Skip to content
ChickenStockChickenStock
ResearchTNGX
Tango Therapeutics logo

Tango Therapeutics (TNGX) stock

NASDAQ

$22.10-8.56%(-2.07)

As of the Nov 17, 2026 close (U.S. Eastern)

Events and reference metrics · 1

Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.

Price date for the multiples · Nov 17, 2026 · Financial period · Trailing twelve months

P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock

P/E

-17.96x

Net loss — not comparable

P/B

3.81x

P/S

60.24x

Find stocks with P/B ≤ 0.9×

Latest earnings

SEC filings

Jul–Sep 2026(FY2026 Q3)

Operating income decreased 657.1% from the same period a year earlier.

Key reported figures come first. Select one to see the same quarter across three years.

See the same quarter across three years →

Filed Nov 9, 2026 · 10-Q · SEC EDGAR

Reported results are from SEC EDGAR filings. Reference information only, not investment advice.

Insider transactions

Recent Form 4 filings grouped by person, date and transaction type.

18 SEC filings
  • Crystal AdamPresident, R&D · Nov 11, 2026Open-market sale5,000 shares · $125K
    Avg. price $25115,743 shares held after
  • Crystal AdamPresident, R&D · Nov 11, 2026Option exercise5,000 shares · $15K
    Avg. price $2.91120,743 shares held after
  • Newcomb JessicaPrincipal Accounting Officer · Nov 2, 2026Open-market sale7,031 shares · $158K
    Avg. price $22.4236
    Show 2 price lots
    • 5,571 shares × $22.2774$124K
    • 1,460 shares × $22.9816$34K
  • Crystal AdamPresident, R&D · Nov 2, 2026Open-market sale5,000 shares · $112K
    Avg. price $22.4215
    Show 2 price lots
    • 3,900 shares × $22.2617$87K
    • 1,100 shares × $22.9882$25K
  • Crystal AdamPresident, R&D · Nov 2, 2026Option exercise5,000 shares · $15K
    Avg. price $2.91120,743 shares held after
  • Crystal AdamPresident, R&D · Oct 1, 2026Open-market sale27,000 shares · $661K
    Avg. price $24.4739
    Show 2 price lots
    • 26,400 shares × $24.4547$646K
    • 600 shares × $25.32$15K
  • Crystal AdamPresident, R&D · Oct 1, 2026Option exercise27,000 shares · $140K
    Avg. price $5.2142,743 shares held after
  • Newcomb JessicaPrincipal Accounting Officer · Sep 22, 2026Open-market sale8,200 shares · $199K
    Avg. price $24.2211
    Show 3 price lots
    • 5,100 shares × $23.9683$122K
    • 2,400 shares × $25.1718$60K
    • 700 shares × $22.8029$16K
  • Crystal AdamPresident, R&D · Sep 1, 2026Open-market sale27,000 shares · $604K
    Avg. price $22.367115,743 shares held after
  • Crystal AdamPresident, R&D · Sep 1, 2026Option exercise27,000 shares · $140K
    Avg. price $5.2142,743 shares held after
  • Crystal AdamPresident, R&D · Aug 3, 2026Open-market sale27,000 shares · $736K
    Avg. price $27.2414
    Show 2 price lots
    • 21,733 shares × $27.3509$594K
    • 5,267 shares × $26.7895$141K
  • Crystal AdamPresident, R&D · Aug 3, 2026Option exercise27,000 shares · $140K
    Avg. price $5.2142,743 shares held after

Only transactions reported on SEC Form 4 are shown. A sale may follow a pre-arranged 10b5-1 plan, and items such as option exercises or shares withheld for taxes are not open-market trades.

Recent SEC filings

40 filings

Filings submitted to the U.S. Securities and Exchange Commission (EDGAR). Dates are SEC filing dates (U.S. Eastern). Form and item names are the official SEC titles. The Earnings and Risk tags come directly from form types and item codes; they are not written by AI. Insider ownership reports (Forms 3, 4 and 5) are excluded.

Company overview

Expand ▾

Tango Therapeutics (TNGX) stock information

NASDAQ

Tango Therapeutics (TNGX) is listed on NASDAQ. Its market capitalization is about $3.7B. On trailing-twelve-month earnings the P/E ratio is -17.96, and the P/B ratio is 3.81. Return on equity is -21.2%. These figures are computed in-house from official filings and are reference information only.

Tango Therapeutics — frequently asked questions

What is the P/E ratio of Tango Therapeutics (TNGX)?
On a trailing-twelve-month basis, TNGX trades at a P/E ratio of -17.96. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
What is the market capitalization of Tango Therapeutics?
TNGX has a market capitalization of about $3.7B. The figure moves with the share price and is refreshed each trading day.
Is this page investment advice?
No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.

All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.